López CN, Sánchez MJI, de Santiago GJI

Idioma: Español
Referencias bibliográficas: 13
Paginas: 720-724
Archivo PDF: 147.89 Kb.

RESUMEN

La quimioterapia neoadyuvante es una opción terapéutica interesante en determinados casos de cáncer de mama. En éstos, el momento de la realización de la biopsia del ganglio centinela supone un tema de controversia actual. Los tumores Her-2-neu y receptores estrogénicos positivos tienen cierta resistencia a la terapia hormonal, especialmente con tamoxifeno. Se presenta un caso con co-expresión de Her-2- neu y receptores estrogénicos que se trató con quimioterapia neoadyuvante y biopsia de ganglio centinela previa. En un segundo tiempo se realizó cirugía conservadora sobre la mama con linfadenectomía axilar, radioterapia y hormonoterapia con letrozol, complementada con goserelina y trastuzumab. La evolución fue muy favorable.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Schwartz GF, Lange AK, Topham AK. Breast conservation following induction chemotheraphy for locally advanced carcinoma of the breast (stages IIB and III). Surg Oncol Clin 1995;4:657-669.

2. Filippakis G, Zografos G. Contraindications of sentinel lymph node biopsy: Are there any really? J Surg Oncol 2007; 5:10.

3. Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer 2010; 116(5): 1243-51.

4. Mushawah FA, Tan MC, Margenthaler JA. Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience. J Surg Oncol. 2010; 102(5):404-7.

5. Mauri D, Pavlidis N, Ioannidos JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:188-94.

6. Charfare H, Limongelli S, Purushotham AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005; 92:14-23.

7. Schwartz GF, Giuliano AE, Veronesi U, and the Consensus Conference Group: Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast. April 19-22, Philadelphia, PA, USA. Breast J2002; 8:126-138.

8. Ellis MJ, Coop A, Singh B, Mauriac L, Llombe rt-Cuss ac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe- Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB- 2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19 (18):3808-16.

9. Gago FE, Fanelli MA, Ciocca DR. Co-expression of steroid hormone receptors (estrogen receptor [alpha] and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mole Biol 2006;98:36-40.

10. Witters LM, Kumar R, Chinchilli VM, Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997;42:1-5.

11. Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 1999;82:46-51.

12. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast Jr 2003;9:361-73.

13. Abdulkareem IH, Zurmi IB. Review of hormonal treatment of breast cancer. Niger J Clin Pract 2012;15(l):9-14.